



## TG Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 6, 2023

### Presentation scheduled for Monday, January 9, 2023 at 9:45 AM PT

NEW YORK, Jan. 06, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will present at the 41<sup>st</sup> Annual J.P. Morgan Healthcare Conference, being held at the Westin St. Francis, in San Francisco, CA. The presentation is scheduled to take place on Monday, January 9, 2023, at 9:45 AM PT.

A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at <http://ir.tgtherapeutics.com/events>.

### ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received approval from the U.S. FDA for BRIUMVI™ (ublituximab-xiyy), for the treatment of adult patients with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. For more information, visit [www.tgtherapeutics.com](http://www.tgtherapeutics.com), and follow us on Twitter [@TGTherapeutics](https://twitter.com/TGTherapeutics) and on [LinkedIn](https://www.linkedin.com/company/tgtherapeutics).

### CONTACT:

#### Investor Relations

Email: [ir@tgtxinc.com](mailto:ir@tgtxinc.com)

Telephone: 1.877.575.TGTX (8489), Option 4

#### Media Relations:

Email: [media@tgtxinc.com](mailto:media@tgtxinc.com)

Telephone: 1.877.575.TGTX (8489), Option 6